We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for nintedanib (Boehringer Ingelheim Pty Ltd)
Active ingredients
nintedanib
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule, soft
Indication
Nintedanib is indicated for the treatment of Systemic Sclerosis (SSc)
Therapeutic area
Immunology